Danish company Bactolife has secured over €30 million in Series B funding to commercialize Binding Proteins, a new food, feed, and dietary supplement ingredient made using precision fermentation.
The funding round was led by Cross Border Impact Ventures (CBIV) and EIFO (Danish Export and Investment Fund), with participation from existing investors Novo Holdings and Athos. The proceeds will be used to execute Bactolife’s human study program across the US, EU, Asia, and LMICs.
The funding will also allow for the scaling of the company’s manufacturing and supply operations to meet global demand, enabling the commercialization of human and animal health ingredients for dietary supplements, functional food and beverages, and feed additives.
With the backing of cornerstone investors, Bactolife plans to launch its first Binding Protein products in the US this year under the ingredient brand Helm™, targeting human health. In the coming years, the company intends to to expand into Asia and Europe, with a commitment to ensuring the technology is accessible to women and children in low- and middle-income countries (LMICs).
“Exciting years ahead”
Bactolife claims that its Binding Proteins are an important step forward in gut health solutions, supporting intestinal resilience through a novel approach that binds and neutralizes unhealthy metabolites. The company previously secured €30 million in Series A funding in 2023.
“Today’s successful close of our Series B round sets the stage for exciting years ahead as we prepare to launch our innovative products in 2026,” said Sebastian Søderberg, CEO of Bactolife. “This funding will enable us to clinically validate, scale, and commercialize our Binding Proteins, taking Bactolife’s solutions to a broad audience. We are excited to welcome new investors to the Bactolife family and are deeply grateful to our existing investors, whose continued support reflects their confidence in our mission. We are ready to transform gut health with novel Binding Proteins.”
